— Know what they know.
Not Investment Advice

STAB OTC

Statera Biopharma, Inc.
1W: -99.0% 1M: -99.5% 3M: -99.0% YTD: -99.7% 1Y: -99.0% 3Y: -99.9%
$0.00
+0.00 (+0.00%)
 
Weekly Expected Move ±54.3%
$-0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 49 · $7142 mcap · 48M float · 0.021% daily turnover · Short 45% of daily vol

Balance Sheet Trends

Total Assets
$21M +1944.4% ▲
5Y CAGR: +5.8%
Total Liabilities
$23M +383.4% ▲
5Y CAGR: +48.8%
Shareholders Equity
-$2M +57.1% ▲
Cash & Investments
$2M +233.3% ▲
5Y CAGR: -33.5%
Total Debt
$16M +711.7% ▲
Net Debt
$14M +922.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$4M$4M$2K$594K$2M
Short-Term Investments$5M$504K$452K$0$135K
Cash & ST Investments$9M$4M$2M$594K$2M
Net Receivables$554K$252K$379K$329K$349K
Inventory$0$0-$424K$0$0
Other Current Assets$234K$103K-$2M$3K$812K
Total Current Assets$10M$4M$2K$926K$4M
Property, Plant & Equip.$0$0$0$110K$1M
Goodwill & Intangibles$0$0$0$0$11M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$49K$58K$34K$0$5M
Total Non-Current Assets$49K$58K$34K$110K$17M
Total Assets$10M$5M$2K$1M$21M
— Liabilities —
Accounts Payable$201K$139K$2M$1M$4M
Short-Term Debt$0$0$2M$2M$5M
Deferred Revenue$0$0-$1M$0$373K
Other Current Liabilities$2M$773K-$1M$0$326K
Total Current Liabilities$2M$912K$2M$5M$11M
Long-Term Debt$0$0$0$0$11M
Other Non-Current Liab.$7K$8K$0$0$0
Total Non-Current Liabilities$7K$8K$0$70K$11M
Total Liabilities$2M$920K$2M$5M$23M
— Equity —
Common Stock$56K$56K$20K$24K$177K
Retained Earnings-$160M-$164M-$16M-$28M-$129M
Accumulated OCI$0-$611K-$568K$0-$7K
Total Stockholders Equity$2M-$1M-$4M-$4M-$2M
Total Liabilities & Equity$10M$5M$2K$1M$21M
— Key Metrics —
Total Debt$0$0$2M$2M$16M
Net Debt-$4M-$4M$2M$1M$14M
Total Investments$5M$504K$452K$0$135K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms